enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Regeneron's blood cancer therapy faces setback as FDA ... - AOL

   www.aol.com/news/regenerons-blood-cancer-therapy...

   Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo

3. US accuses Regeneron of fraudulent price reporting for eye drug

   www.aol.com/news/us-justice-department-files...

   BOSTON (Reuters) -The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals of manipulating Medicare's drug-pricing process by inflating the average sales price for its expensive ...

4. US FDA declines to approve Regeneron's higher-dose Eylea ...

   www.aol.com/news/us-fda-declines-approve...

   Regeneron's shares closed down 8.6% at $715.9. The U.S. Food and Drug Administration issued a complete response letter, indicating the agency has review US FDA declines to approve Regeneron's ...

5. US FDA declines to approve Regeneron's blood cancer therapy - AOL

   www.aol.com/news/us-fda-declines-approve...

   Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment. The ...

6. What's Going On With Regeneron Pharmaceuticals Stock On ... - AOL

   www.aol.com/whats-going-regeneron...

   On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending ...

7. Regeneron Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Regeneron_Pharmaceuticals

   Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...

8. Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? - AOL

   www.aol.com/why-regeneron-pharmaceuticals-stock...

   On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...

9. Regeneron beats quarterly results on strong demand for ... - AOL

   www.aol.com/news/regeneron-beats-quarterly...

   Regeneron reported an adjusted profit of $11.56 per share on total revenue of $3.55 billion for the quarter, above analysts' estimates of $10.61 per share and $3.38 billion, according to LSEG data.